Gattig P., Langguth P.: Computer-aides assurance of Risk documentation within an existing FMEA landscape. Pharm.Ind. (2019) 6;851-856
Siewert C, Haas H, Nawroth T, Ziller A, Nogueira SS, Schroer MA, Blanchet CE,Svergun DI, Radulescu A, Bates F, Huesemann Y, Radsak MP, Sahin U, Langguth P. Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems. Biomaterials. 2019 Feb;192:612-620. doi:10.1016/j.biomaterials.2018.10.020
Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, Andreas CJ, Schaefer KJ, Mann J, McAllister M, Jamei M, Kostewicz E, Kesisoglou F, Langguth P, Minekus M, Müllertz A, Schilderink R, Koziolek M, Jedamzik P, Weitschies W, Reppas C, Augustijns P. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. (2019) 136:70-83. doi: 10.1016/j.ejpb.2018.12.010.
Hofmann M, Thieringer F, Nguyen MA, Månsson W, Galle PR, Langguth P. A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations. Eur J Pharm Biopharm. (2019) 136: 192-202. doi: 10.1016/j.ejpb.2019.01.010.
Kubbinga M, Augustijns P, García MA, Heinen C, Wortelboer HM, Verwei M, Langguth P. The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. Eur J Pharm Biopharm. (2019) 136: 147-155. doi:10.1016/j.ejpb.2019.01.021.
Ciciliani AM, Langguth P, Wachtel H. Handling forces for the use of different inhaler devices. Int J Pharm. (2019) 560: 315-321. doi:10.1016/j.ijpharm.2019.01.053.
Soisuwan S, Teeranachaideekul V, Wongrakpanich A, Langguth P, Junyaprasert VB. Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals. Eur J Pharm Biopharm. (2019) 137: 68-76. doi:10.1016/j.ejpb.2019.02.004.
Al-Gousous J, Ruan H, Blechar JA, Sun KX, Salehi N, Langguth P, Job NM, Lipka E, Loebenberg R, Bermejo M, Amidon GE, Amidon GL. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications.
Eur J Pharm Biopharm. (2019) 139: 47-58. doi:10.1016/j.ejpb.2019.03.012.
Zaheer K, Langguth P. Designing robust immediate release tablet formulations avoiding food effects for BCS class 3 drugs. Eur J Pharm Biopharm. (2019) 139: 177-185. doi: 10.1016/j.ejpb.2019.03.015.
Al-Gousous J, Salehi N, Amidon GE, Ziff RM, Langguth P, Amidon GL. Mass Transport Analysis of Bicarbonate Buffer: Effect of the CO(2)-H(2)CO(3) Hydration-Dehydration Kinetics in the Fluid Boundary Layer and the Apparent Effective p K(a) Controlling Dissolution of Acids and Bases. Mol Pharm. (2019) 16(6): 2626-2635. doi: 10.1021/acs.molpharmaceut.9b00187.
2018
Henze LJ, Griffin BT, Christiansen M, Bundgaard C, Langguth P, Holm R. Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide. Eur J Pharm Sci. (2018) 118:183-190. doi:10.1016/j.ejps.2018.03.017.
Schnorr J, Fütterer S, Spicher K, Catarinolo M, Schlösser C, Enzmann H, Langguth P. Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition. Regul Toxicol Pharmacol.(2018) 94:293-298. doi: 10.1016/j.yrtph.2018.02.009
Al-Gousous J, Langguth P. A time-scaled convolution approach to construct IVIVC for enteric-coated acetylsalicylic acid tablets. Pharmazie. (2018) 73(2):67-69. doi: 10.1691/ph.2018.7136.
M. Alhatem, K. Zaheer, H. Potthast, P. Langguth. Intakte versus zerkleinerte Tabletten – Biopharmazeutische Beurteilung von Metformin- und Ibuprofen-haltigen Fertigarzneimitteln. Krankenhauspharmazie (2018) 39(8): 343-354
S. Suwicha, V. Teeranachaideekul, A. Wongrakpanich, P. Langguth, V. B. Junyaprasert. In vitro performance and cellular uptake of clarithromycin nanocrystals produced by media milling technique. Powder Technology (2018) https://doi.org/10.1016/j.powtec.2018.07.036
Plöger GF, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Parr A, Polli JE, Shah VP, Tajiri T, Dressman JB. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. J Pharm Sci. (2018) 107(7):1761-1772. doi: 10.1016/j.xphs.2018.03.009
Dahlgren D, Roos C, Johansson P, Tannergren C, Lundqvist A, Langguth P, Sjöblom M, Sjögren E, Lennernäs H. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs. Int J Pharm. (2018) 547(1-2)158-168. doi: 10.1016/j.ijpharm.2018.05.029.
Hens B, Sinko PD, Job N, Dean M, Al-Gousous J, Salehi N, Ziff RM, Tsume Y, Bermejo M, Paixão P, Brasseur JG, Yu A, Talattof A, Benninghoff G, Langguth P, Lennernäs H, Hasler WL, Marciani L, Dickens J, Shedden K, Sun D, Amidon GE, Amidon GL. Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project. Int J Pharm. (2018) 548(1) 120-127. doi: 10.1016/j.ijpharm.2018.06.050.
Burak C, Wolffram S, Zur B, Langguth P, Fimmers R, Alteheld B, Stehle P, Egert S. Effect of alpha-linolenic acid in combination with the flavonol quercetin on markers of cardiovascular disease risk in healthy, non-obese adults: A randomized, double-blinded placebo-controlled crossover trial. Nutrition. (2019) 58: 47-56. doi: 10.1016/j.nut.2018.06.012.
Al-Gousous J, Sun KX, McNamara DP, Hens B, Salehi N, Langguth P, Bermejo M, Amidon GE, Amidon GL. Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO(2) Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. Mol Pharm. (2018) 15(11): 5291-5301. doi: 10.1021/acs.molpharmaceut.8b00783
Siewert C, Haas H, Nawroth T, Ziller A, Nogueira SS, Schroer MA, Blanchet CE,Svergun DI, Radulescu A, Bates F, Huesemann Y, Radsak MP, Sahin U, Langguth P. Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems. Biomaterials. 2019 Feb;192:612-620
2017
González-García I, Mangas-Sanjuan V, Merino-Sanjuán M, Álvarez-Álvarez C, Díaz-Garzón Marco J, Rodríguez-Bonnín MA, Langguth T, Torrado-Durán JJ, Langguth P, García-Arieta A, Bermejo M. IVIVC approach based on carbamazepine bioequivalence studies combination. Pharmazie. (2017) 72(8):449-455.
2016
M. Knopp, P. Langguth et al. (2016): Influence of copolymer composition on in vitro and in vivo performance of celecoxib-PVP/VA amorphous solid dispersions. AAPS Journal in press
M. M. Knopp, J.H. Nguyen, C. Becker, N.M. Francke, E.B. Jørgensen, P. Holm, R. Holm, H. Mu, T. Rades, P. Langguth (2016): Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions. Eur. J. Pharm. Biopharm. In press
V. Brüll, C. Burak, B. Stoffel-Wagner, S. Wolffram, G. Nickenig, C. Müller, P. Langguth, B. Alteheld, R. Fimmers, P. Stehle, S. Egert (2016): Acute intake of quercetin from onion skin extract does not influence postprandial blood pressure and endothelial function in overweight-to-obese adults with hypertension: a randomized, double-blind, placebo-controlled, crossover trial. Eur. J. Nutr. DOI 10.1007/s00394-016-1185-1
2015
K. Spicher, S. Brendler-Schwaab, C. Schlösser, M. Catarinolo, S. Fütterer, P. Langguth, H. Enzmann (2015): Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Reg. Toxicol. And Pharmacol. 73: 65-72
J. Al-Gousous and P. Langguth (2015): Oral dosage form disintegration – the forgotten process. J. Pharm. Sci. DOI:10.1002/jps.24303
J. Al Gousous, M. Penning, P. Langguth (2015): Molecular insights into shellac film coats from different aqueous shellac salt solutions and effect on disintegration of enteric-coated soft gelatin capsules. Int. J. Pharm. 484(1-2): 283-291
M. Kubbinga, M.A. Nguyen, P. Staubach, S. Teerenstra, P. Langguth (2015): The Influence of chitosan on the oral bioavailability of acyclovir - A comparative bioavailability study in humans. Pharm. Res. DOI:10.1007/s11095-014-1613-y
J. Al-Gousous and P. Langguth (2015): European versus United States Pharmacopoeia-specified disintegration testing for enteric-coated soft gelatin capsules. Dissolution Technologies 22(3)
M. Knopp, N.E. Olesen, P. Holm, K. Loebmann, R. Holm, P. Langguth, T. Rades (2015): Evaluation of drug-polymer solubility curves through formal statistical analysis. Comparison of preparation techniques. J. Pharm. Sci. 104(1) 44-51
T. Peters, C. Grunewald, M. Blaikner, M. Ziegner, C. Schütz, D. Iffland, G. Hampel, T. Nawroth, P. Langguth (2015): Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy. Radiat. Oncol. 10(1):52 doi: 10.1186/s13014-015-0342-7
P. Khoshakhlagh, R. Johnson, P. Langguth, T. Nawroth, L. Schmueser, N. Hellmann, H. Decker, N.K. Szekely (2015): Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development. J Pharm Sci. 2015 May 11. doi: 10.1002/jps.24470
V. Brüll, C. Burak, B. Stoffel-Wagner, S. Wolffram, G. Nickenig, C. Müller, P. Langguth, B. Alteheld, S. Naaf, B.F.Zimmermann, P. Stehle, S. Egert (2015): Effects of a quercetin-rich onion skin extract on 24h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomized double-blinded placebo-controlled crossover trial. Br. J. Nutr. 114(8): 1263-77. Doi: 10.1017/S0007114515002950.
S. Kindgen, H. Wachtel, B. Abrahamsson, P. Langguth (2015): Computational Fluid dynamics simulation of hydrodynamics and stresses in the PhEur/USP disintegration tester under fed and fasted fluid characteristics. J Pharm Sci. 2015 May 27. doi:10.1002/jps.24511
K. Spicher, S. Brendler-Schwaab, C. Schlösser, M. Catarinolo, S. Fütterer, P. Langguth, H. Enzmann (2015): Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Reg. Toxicol and Pharmacol. 73: 65-72
M.A. Nguyen, P. Staubach, S. Wolffram, P. Langguth (2015): The influence of single-dose and short-term-administration of quercetin on the pharmacokinetics of midazolam in humans. J. Pharm. Sci. doi: 10.1002/jps.24500
M.M. Knopp, N.E. Olesen, P. Holm, P. Langguth, R. Holm, T. Rades (2015): Influence of polymer molecular weight on drug-polymer solubility: A comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer. J. Pharm. Sci. doi: 10.1002/jps.24410
T. Schmitz, N. Bassler, M. Blaickner, M. Ziegner, M.C. Hsiao, Y.H. Liu, H. Koivunoro, I. Auterinen, T. Serén, P. Kotiluoto, H. Palmans, P. Sharpe, P. Langguth, G. Hampel (2015): The alanine detector in BNCT dosimetry: dose response in thermal and epithermal neutron fields. Med Phys. 42(1):400-11
M.A. Nguyen, P. Staubach, I. Tamai, P. Langguth (2015): High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans. Eur. J. Pharm. Sci. 68: 36-42
M. Penning, P. Langguth (2015) Schellack. Kommentar zur PhEur 8.0, Wissenschaftliche Verlagsgesellschaft Stuttgart
M.D. Donovan, J.E. Polli, P. Langguth, I. Tamai, B. Vig, L.X. Yu (2015) Gordon L. Amidon: Very sustained drug absorption. J. Pharm. Sci. Doi: 10.1012/jps.24523
M. Petrusevska, S. Berglez, I. Krisch, I. Legen, K. Megusar, L. Peternel, B. Abrahamsson, R. Cristofoletti, D.W. Groot, S. Kopp, P. Langguth, M. Mehta, J.E. Polli, V.P. Shah, J. Dressman (2015) Biowaiver monographs for immediate release solid oral dosage forms: Levetiracetam. J. Pharm. Sci. Doi: 10.1002/jps.24350
Meinhardt K, Morakul B, Holm R, Junyaprasert V, Langguth P: Ussing Chamber based Integrated Dissolution/ Permeation with Caco-2 or Rat Duodenum Membranes and Systemic Exposure Following Oral Administration of Clarithromycin Suspensions. Innovative Medicines Initiative: Oral Biopharmaceutic Tools, Annual Meeting. June 30th- July 2nd 2015, Paris.
R. Rach, S. Kindgen, T. Nawroth, B. Abrahamsson, P. Langguth (2015): A Modified Disintegration Tester For Solid Dosage Forms: Influence of Motion and Velocity Profiles on Disintegration Behaviour. Innovative Medicines Initiative: Oral Biopharmaceutic Tools, Annual Meeting. June 30th - July 2nd 2015, Paris.
M.Denny, P.Stein, M.Radsak, P.Langguth (2015): "Nanoparticle dispersed formulation IMI-GEL vs. Aldara® in human - a comparative Phase-I Study" on 1. FZI-Retreat, 19. - 20.06.2015 in Seeheim-Jugenheim
M. A. Nguyen, T. Flanagan, M. Brewster, F. Kesisoglou, P. Langguth (2014): A survey on past success and failures with IVIVC approaches. Poster presentation. Innovative Medicines Inittiative: Oral Biopharmaceutics Tools, Annual Meeting. Stevenage, UK. May 12-14th
M. Kubbinga. Impact of excipients on systemic exposure - Result of experimental investigations, EUFEPS BABP Network Global Bioequivalence Harmonisation Initiative; March 23-24, 2015, Amsterdam, The
2014
M. A. Nguyen (2014): Pharmacokinetic Drug-Nutraceutical Interactions: A Particular Type of Food-Drug Interaction. Oral presentation. DPhG Annual Meeting. Frankfurt, Germany. September 23-26th
Meinhardt K, Khoshakhlagh P, Konerding M A, Nawroth T, Langguth P: Use of Simulated Intestinal Fluid Solutions with Rat Intestine in Dissolution/Permeation Experiments. DPhG Annual Meeting. September 23-26th 2014, Frankfurt
Meinhardt K, Khoshakhlagh P, Nawroth T, Langguth P: Use of Simulated Intestinal Fluid Solutions in integrated dissolution/ permeation models for poorly soluble drugs with rat intestine. Innovative Medicines Initiative: Oral Biopharmaceutic Tools, Annual Meeting. May 12-14th 2014, Stevenage
M. Hofmann, M. A. Nguyen, F. Thieringer, F. K. Rahman, W. Mansson, G. L. Amidon, P. Langguth (2014): In vivo dissolution rates of ibuprofen suspensions in healthy volunteers. Poster presentation. APS meeting & OrBiTo Annual meeting. Stevenage, UK. 12-14 May 2014
M. Kubbinga, Biowaiver extensions through the QbD concept?, OrBiTo Workshop; 17-19 September 2014, Mainz, Germany
M. Kubbinga, P.Langguth, Excipients and the bioavailability of oral medicines, poster presentation, CBG Wetenschapsdag January 2014, Utrecht, The Netherlands, www.regulatoryscience.nl
2013
M. A. Nguyen, P. Staubach, S. Wolffram, P. Langguth (2013): Absorption and disposition of talinolol and quercetin following concomitant administration in healthy subjects. Poster presentation. German Pharmaceutical Society (DPhG) Annual Meeting. Freiburg, Germany. October 9-11th
M. A. Nguyen (2013): Developing a predictive mathematical model for the negative food effect of BCS class III compounds in solid drug formulations. Oral presentation. Innovative Medicines Initiative: Oral Biopharmaceutic Tools, Work Package 4 Annual Meeting. Sheffield, UK. March 1st
M. A. Nguyen, F. Thieringer, F. K. Rahman, G. L. Amidon, P. Langguth (2013): Dissolution rates of BCS class II compounds in healthy volunteers. Poster presentation. Innovative Medicines Initiative: Oral Biopharmaceutics Tools, Annual Meeting. Uppsala, Sweden. June 25-26th
M. A. Nguyen, P. Staubach, S. Wolffram, I. Tamai, P. Langguth (2013): Effects of quercetin and naringin on the pharmacokinetics of talinolol in healthy volunteers. Poster presentation. World Conference of Drug Absorption, Delivery and Transport. Uppsala, Sweden. June 24-26th
Robert Winkler, Herbert Wachtel, Peter Langguth: Dose Range of a Propellant Driven High-Dose Dry Powder Inhaler
RDD Europe 2013 (2013), Vol 2, pp 251-256
2012
Robert Winkler, Herbert Wachtel, Peter Langguth: Development of a Propellant-Activated Multi-High-Dose Dry Powder Inhaler
Respiratory Drug Delivery 2012 (2012), Vol 2, pp 559-564
A. Sediq, M. Kubbinga, D. Barends, P. Langguth, J. Dressman, The impact of the EMA change in definition of ‘Dose’ on the BCS dose/solubility ratio: a review, poster presentation, 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey, 19-22 March 2012
Buch, K., Peters, T., Nawroth, T., Sänger, M., Schmidberger, H., Langguth, P. Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay – a comparative study. Radiat. Oncol. 2012 Jan 3;7:1.
2011
M. Kubbinga, Biowaivers by in-vitro BE studies: Update on science & regulations, Informa Life Sciences, Budapest, Hungary, 17-18 May 2011
Nawroth, T., Buch, P., Buch, K., Langguth, P., Schweins, R. Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod) estimated by combined time-resolved neutron and dynamic light scattering. Mol. Pharm. 2011 Dec 5;8(6):2162-72.
Nawroth, T., Buch, K., Peters, T., Langguth, P., Hofmann, A.M., Frey, H., Pairet, B., Decker, H., Sänger, M., Schmidberger, H. Lokale Strahlentherapie mit Enhancer-Nanopartikeln. Poster presentation at the meeting TumorBioMedizin 2011, Mainz.
Nawroth, T., Buch, K., Peters, T., Buch, P., Wurster, E.C., Hühn, E., Heinen, C., Langguth, P., Pairet, B., Meesters, C., Decker, H., Hofmann, A.M., Frey, H., Grunewald, C., Hampel, G., Sänger, M., Schmidberger, H., Alexiou, C., Corde, S., Bravin, A., Le Duc, G., Requardt, H., Boesecke, P., Lauss, B., Jentschel, M., Watkins, E., Schweins, R., May, R., Callow, P. Target Nanoparticles – Enhancer-Drug Carriers for local Radio Therapy of Cancer. Poster presentation at the DPhG annual meeting 2011, Innsbruck.
Nawroth, T., Pairet, B., Decker, H., Buch, K., Peters, T., Buch, P., Heinen, C., Hühn, E., Wurster, E.C., Langguth, P., Hofmann, A.M., Frey, H., Schmidberger, H., Alexiou, C., Goerigk, G., Boesecke, P., Bravin, A., Le Duc, G., Watkins, E., May, R., Callow, P., Schweins, R. Bio-Nanoparticles for Medical Applications – Enhancer Radiotherapy – SANS, DLS & ASAXS. Conference ‘Neutrons in Biology’ 2011, Grenoble
2010
Nawroth, T., Peters, T., Wurster, E.C., Buch, K., Buch, P., Hühn, E., Langguth, P., Decker, H., Hampel, G., Hofmann, A.M., Frey, H., Schmidberger, H., Alexiou, C., May, R., Callow, P., Schweins, R., Boesecke, P., Le Duc, G., Bravin, A. Target Nanoparticles – Drug Carriers for Enhancer Radiation Therapy of Cancer. Poster presentation at the conference ‘Frontiers in Medicinal Chemistry’ 2010, Münster
Buch, K., Nawroth, T., Schweins, R., Langguth, P. Characterization of Poly(lactic-co-glycolic acid) nanoparticles containing lanthanides. Poster presentation at the DPhG annual meeting 2010, Braunschweig.
2009
Buch, K., Penning, M., Wächtersbach, E., Maskos, M., Langguth, P. Investigation of various shellac grades: additional analysis for identity. Drug Dev. Ind. Pharm. 2009 Jun; 35(6):694-703.
M. Kubbinga, P. Langguth, D.Barends, BIOTHREE: Comparative in vitro permeability testing - a new surrogate bioequivalence test, poster presentation, Strategies in Oral Drug Delivery 2009, Garmisch-Partenkirchen, Germany, 8-13 March 2009
Nawroth, T., Peters, T., Buch, P., Buch, K., Hühn, E., Glube, N., Langguth, P., Pairet, B., Meesters, C., Decker, H., Bickes-Kelleher, D., Schmidberger, H., Lauss, B., Jentschel, M., Gähler, R., May, R.P., Callow, P., Corde, S., Boesecke, P., Bravin, A., Le Duc, G. Nano-RT: Radiation Therapy and Imaging with Target Liposomes and Nanoparticles. Poster presentation at the conference ‘Symposium on Phospholipids in Pharmaceutical Research’ 2009, Heidelberg.
2007
D. Bickmann, H. Wachtel, P. Langguth (2007):
Simulating particle deposition in an idealized human throat – CFD results in comparison to experimental data. PARTEC World Congress on Particle Technology, Nürnberg, 27. – 29. März
C. Weiler, M. Wolkenhauer, M. Trunk, P. Langguth (2007):
Dry powder deagglomeration of spherical, micron and submicron particles. PARTEC World Congress on Particle Technology, Nürnberg, 27.-29. März
M.Tubic-Grozdanis, H.Spahn-Langguth, P. Langguth (2007)
Simulation of non-linear dose dependent absorption and pharmacodynamic response of P-glycoprotein substrate talinolol. Poster 4th World Conference on Drug Absorption,Transport and Delivery(WCDATD)in Kanazawa, Japan, June 20-22
M. Tubic-Grozdanis, P.Langguth (2007)
Simulation of non-linear dose dependent absorption and pharmacodynamic response of P-glycoprotein substrate talinolol. Kurzvortrag 4th World Conference on Drug Absorption, Transport and Delivery (WCDATD) in Kanazawa, Japan, June 20-22
F.E. Alemdaroglu, N.C. Alemdaroglu, P. Langguth, A. Herrmann (2007):
DNA block copolymer micelles: Synthesis, morphologies and interactions with living systems. 234. ACS National Meeting, Division of Polymer Chemistry, Boston, 19.-23. August
P. Langguth, M. Tubic-Grozdanis (2007)
BCS - Current issues and extension of biowaivers to compounds beyond class I. Vortrag Symposium BIOFARM 2007 “In Vitro Dissolution Testing: Role in Biopharmaceutical Characterization of Drug Products”, Belgrad, September 27th
P. Langguth, H.E. Elgabarty, M. Ofer, H. Spahn-Langguth (2007):
Structure-affinity considerations for flavonoids & steroids at the organic cation transporter. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Erlangen, 10.-13. Oktober
G. Shazly, P. Langguth (2007)
Lipid composition and structure affect drug release from liposomes. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Erlangen, 10.-13. Oktober
M. Jahn, P. Langguth (2007)
Dependence of oxidative stress exerted by colloidas iron formulations on carbohydrate carrier. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Erlangen, 10.-13. Oktober
T. Nawroth, P. Buch, G. Shazly, P. Langguth, B. Pairet, H. Decker, H. Schmidberger, Ch. Alexiou (2007)
Nanoparticles for indirect radiation therapy IRT. Kurzvortrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Erlangen, 10.-13. Oktober
C. Weiler, M. Trunk, P. Langguth (2007)
Dispersibility of spray-dried powders for inhalation. Kurzvortrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Erlangen, 10.-13. Oktober
T. Könnecke, G. Moddelmog, P. Langguth (2007):
Influence of different directly compressible mannnitol grades on dissolution of low soluble fenofibrate. 2007 AAPS Annual Meeting, San Diego, CA, 11.-15. November
2006
M.Tubic, P.Langguth (2006):
Absorption profile of the P-gp substrate talinolol in humans following administration of controlled-release versus immediate-release tablets. Poster at the 45th International Controlled-release EUDRAGIT® Workshop, Darmstadt, February 21.-22.
M. Tubic-Grozdanis, H. Spahn-Langguth, M. Bolger, P. Langguth (2006):
Prediction of the pharmacokinetics of the P-gp substrate talinolol administered as controlled release dosage form using a physiological based absorption model. EUFEPS Conference Membrane Drug Transporters: Impact on Drug Discovery, Development, Regulation and Usage. Copenhagen 25.-27. September
P. Langguth, T. Lenhardt (2006):
Enhancing systemic availability with nanoparticle formulations. ESF-UB Conference “Nanomedicine – A new opportunity for improving diagnosis, prevention and treatment for disease. European Science Foundation, Sant Feliu de Guixols, Spain, 15.-20. September
N.C. Alemdaroglu, S. Wolffram, H. Spahn-Langguth, P. Langguth (2006):
In vitro reduction of intestinal folic acid uptake by green tea catechins. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Marburg, 4.-7. Oktober
M. Tubic-Krozdanis, H. Spahn-Langguth, P. Langguth (2006):
Efficiency of the validated in silico model to predict the absorption of the P-glycoprotein substrate talinolol from controlled release dosage forms. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Marburg, 4.-7. Oktober
C. Weiler, M. Trunk, P. Langguth (2006):
Relaxation time measurements of amorphous powders for inhalation. Kurzvortrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft Marburg, 4.-7. Oktober
T. Könnecke, G. Moddelmog, P. Langguth (2006)
Mannitol modification and particle size of low soluble fenofibrate affect dissolution. Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Marburg, 4.-7. Oktober
K. Buch, M. Hausding, S. Finotto, P. Langguth (2006)
MicroSprayer® – eine intratracheale Alternative zur pulmonalen Applikation von Mikrosphären an Mäusen. Poster X. Deutsches Aerosol Therpie Seminar in Marburg, 10.-11. November
T. Könnecke, G. Moddelmog, P. Langguth (2006):
Influence of beta and delta mannitol on dissolution of low soluble fenofibrate. AAPS Annual Meeting, San Antonio, TX, Oct. 29 – Nov. 2.
M. Tubic-Grozdanis, P. Langguth (2006)
Prediction of biopharmaceutic performance of immediate versus controlled release dosage forms using a physiologically based absorption model. Lecture at 4th Congress of pharmacists of Serbia "Modern Pharmacy - Enhancing Health and the Quality of Life" with international participation, Belgrade/Serbia, 28th November - 2nd December 2006
2005
M. Ofer, A. Hanafy, D. Frenzel, S. Wolffram, P. Langguth, H. Spahn-Langguth (2005):
Flavonoids may delay talinolol absorption: In-situ and in-vivo studies in rats. 3rd World Conference on Drug Absorption, Transport and Delivery, Barcelona 18.-20. April.
T. Mau, V. Hartmann, J. Burmeister, P. Langguth, H. Häusler (2005):
Sterilisation of a plastic container closure system by ethylene oxide. 1st European Congress on Life Sciences Process Technology, Nürnberg, 11.-13. Oktober
D. Bickmann, H. Wachtel, P. Langguth (2005):
Influence of breathing patterns on the particle deposition of aerosols in the human throat. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T09. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
I. Schöttle, G. Böck, H. Bender, P. Langguth (2005):
Characterization of spray-dried PLA/PLGA microparticles for controlled release. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T37. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
M. Tubic, D. Wagner, H. Spahn-Langguth, M. Bolger, P. Langguth (2005):
Prediction of non-linear absorption profile for the P-gp substrate talinolol using an in silico approach. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T43. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
N. Glube, P. Langguth (2005):
Characterization of a human renal carcinoma cell line for transport processes via the SLC22 family of transporters. Jahrestagung der Deutschen Pharma¬zeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T17. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
M. Ofer, P. Langguth, H. Spahn-Langguth (2005):
Bidirectional membrane transport: simulations of transport inhibition in uptake studies. Jahrestagung der Deutschen Pharma¬zeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T54. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
T. Könnecke, G. Moddelmog, P. Langguth (2005):
Different direct compressible mannitol grades affect dissolution of low soluble fenofibrate. Jahrestagung der Deutschen Pharma¬zeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T55. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
N.C. Alemdaroglu, H. Spahn-Langguth, P. Langguth (2005):
Interaction between antiepileptics and folic acid is not related to intestinal transport inhibition. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T02. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
B. Beilmann, P. Langguth, P. Graß, H. Häusler (2005):
Development HPLC of lactose applied to determine fine particle dose of carrier in DPI´s. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz, vom 5. bis 8. Oktober 2005. Abstract #T07. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-016844-3.
C. Isbasar, H. Spahn-Langguth, P. Langguth (2005):
Antiepileptic drugs do not inhibit folic acid uptake in human Caco-2 monolayer. BioMedical Transporters 2005 – Bridging Basic and Applied Sciences, St. Gallen, Switzerland, 14.-18. August.
N. Glube, P. Langguth (2005):
A human renal cell line as an in vitro model for the active uptake of organic cations via the SLC22 family of transporters. BioMedical Transporters 2005 – Bridging Basic and Applied Sciences, St. Gallen, Switzerland, 14.-18. August.
2004
H. Spahn-Langguth, M. Ofer, C. Hilgendorf, P. Langguth (2004):
MDR-1-transfection and P-Glycoprotein induction studies including talinolol as P-gp probe.
45. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, vom 9.-11. März 2004. Veröffentlicht in Naunyn-Schmiedeberg´s Archives of Pharmacology Vol. 369, Suppl. 1, R3.
M. Ofer, Y. Shirasaka, P. Langguth, S. Yamashita, H. Spahn-Langguth (2004):
Inhibition of OCT-mediated transport by carvedilol and its major metabolites.
Poster 2nd World Congress of the Board of Pharmaceutical Sciences of FIP, Kyoto, Japan vom 30. Mai – 3. Juni 2004.
M. Ofer, P. Langguth, W.J. Zeller, H. Spahn-Langguth (2004):
The use of parental and mdr1-transfected ovarian carcinoma cell lines to study transport modula¬tion by flavonoids.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg, vom 7. bis 9. Oktober 2004. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-014723-3
I. Schöttle, G. Böck, H. Bender, P. Langguth (2004):
Characterization of spray-dried PLGA microparticles loaded with budesonide.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg, vom 7. bis 9. Oktober 2004. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-014723-3
B. Beilmann, P. Langguth, P. Graß, H. Häusler (2004):
Influence of capsules on the aerosolization characteristics of dry powder inhalation products.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg, vom 7. bis 9. Oktober 2004. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-014723-3
P. Langguth, M. Ofer, Y. Shirasaka, S. Yamashita, H. Spahn-Langguth (2004):
Inhibition of OCT-mediated transport by carvedilol and ist major metabolites.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg, vom 7. bis 9. Oktober 2004. Abstracts veröffentlicht in den Proceedings der Jahrestagung, ISBN 3-00-014723-3.
2003
C. Leisen, A. Hanafy, P. Langguth, H. Spahn-Langguth (2003):
Creatine and taurine affect absorption of baclofen and structural congeners: Implications for kinetic interactions between drugs and energy drink ingredients?
44. Frühjahrstagung der DGPT vom 17. bis 20. März, 2003.
P. Langguth, U. Hartung (2003):
Iron complex formulations for parenteral administration differ in terms of stability and release rate in serum.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
S. Härtter, U. Schmitt, A. Abou el-ela, L. J. Guo, H. Glavinas, P. Krajcsi, J. M. Baron, C. Hiemke, P. Langguth (2003):
ABCB1/P-Glycoprotein (P-gp) affects PK/PD of the atypical antipsychotic amisulpride. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
M. Ofer, A. Koggel, H. Spahn-Langguth, P. Langguth (2003):
Drug transport modulation by selected flavonoids not related to P-gp affinities: Involvement of OCT?
Drug Discovery Symposium, 24.-26. September, Pfizer Ltd., Sandwich, UK.
N. Bradry, A. Hanafy, D. Wagner, P. Langguth, H. Spahn-Langguth (2003):
Concentration-dependent absorption characteristics and vinblastine effects in intestinal perfusion studies with ciprofloxacin and talinolol.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
C. Seidel, H. Spahn-Langguth, P. Langguth (2003):
Intestinal permeabilities of budesonide using the single-pass intestinal perfusion method in the rat.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
P. Langguth, U. Hartung (2003):
Iron complex formulations for parenteral administration differ in terms of stability and release rate in serum.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
M. Ofer, P. Langguth, A. Koggel, C. Hilgendorf, H. Spahn-Langguth (2003):
Celiprolol, talinolol and pindolol intestinal absorption: The role of OCT in membrane transport.
Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Würzburg, vom 8. bis 11. Oktober 2003.
A. Abou el ela, S. Härtter, C. Hiemke, A. Koggel, H. Spahn-Langguth, P. Langguth (2003):
P-glycoprotein-mediated secretion of 14 psychoactive drugs across biomembranes.
Doktorandentagung der Deutschen Pharmazeutischen Gesellschaft, Düsseldorf, vom 7.3. bis 9.3.2003.
2002
D. Wagner, N. Glube, P. Langguth (2002):
Different buffers affect the solubility of talinolol and its dissolution from solid dosage forms.
Posterbeitrag DPhG-Jahrestagung in Berlin vom 09. bis 13. Oktober 2002. Abstract veröffentlicht in Arch. Pharm. 335 (Suppl. 1) 123.
K. Brodka-Pfeiffer, P. Langguth, H. Häusler, P. Graß (2002):
Einfluss der Mikronisierung auf die physikalische Stabilität von Salbutamolsulfat für Pulverinhalatoren. Posterbeitrag DPhG-Jahrestagung in Berlin vom 09. bis 13. Oktober 2002. Abstract veröffentlicht in Arch. Pharm. 335 (Suppl. 1) 109.
S. Härtter, A. Abouelela, P. Langguth, S. Hüwel, T. Lohmann, C. Hiemke, H.-J. Galla (2002):
Permeation of the atypical neuroleptics amisulpride and clozapine across an artificial blood-brain- and blood-liquor barrier. EUFEPS European Congress “New Safe Medicines Faster”, 20-23. Oct., Stockholm.
M. Ofer, S. Wolffram, H. Spahn-Langguth, P. Langguth (2002):
Characterization of multi-drug-resistant ovarial-carcinoma-cells as model for P-glycoprotein-mediated transport. 18th Meeting of the European Intestinal Transport Group, 28. Sept. – 1. Okt., Egmond aan Zee, Niederlande. Abstract veröffentlicht in J. Physiol. Biochem. 58: 292
A. Koggel, H. Spahn-Langguth, P. Langguth (2002):
Interaction of beta-adrenoceptor antagonists with P-glycoprotein. Correlation between drug lipophilicity and binding properties in vitro. 4th European Graduate Student Meeting in Frankfurt/Main, 8.-10. Februar.
A. Koggel, H. Spahn-Langguth, P. Langguth (2002):
Intestinal absorption of quaternary ammonium compounds – Involvement of P-glycoprotein in the limited oral bioavailability. Drug Discovery Symposium, 12.-13. September, Pfizer Ltd., Sandwich, UK.
C. Leisen, A. Hanafy, P. Langguth, H. Spahn-Langguth (2002):
Taurine- and caffeine-containing energy drinks: Luminal presence of taurine reduces baclofen intestinal absorption in rats. Drug Discovery Symposium, 12.-13. September, Pfizer Ltd., Sandwich, UK.
T. Mau, V. Hartmann, P. Langguth, H. Häusler (2002):
Sterilisation of a production machine by vaporized hydrogen peroxide.
Vortrag 47th Annual Congress of APV and APGI 10th International Conference on Pharmaceutical Technology, 4th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Florenz, 8. – 11. April, veröffentlicht in Proceedings 4th World Meeting APV/APGI, Florenz.
2001
H. Spahn-Langguth, P. Langguth (2001):
Absorption of the P-glycoprotein substrate talinolol and the influence of concomitant administration of grapefruit juice.
Poster 17. Meeting of the European Intestinal Transport Group, Barcelona, Spain, 5.-8. Mai 2001.
Dressler C., Neuhoff S., Andersson T., Regårdh C.G., Leisen C., Langguth P., Spahn-Langguth H (2001):
The duration of culturing may affect active transport in Caco-2 cells: Amino acid and peptide transporter versus P-Glycoprotein.
Posterbeitrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Halle vom 10. – 13. Oktober 2001 in Halle/Saale. Abstract veröffentlicht in Arch. Pharm. 334 Suppl. 2, 34
Becker M., Fuchs S., Schmidt C., Langguth P. (2001):
Pharmaceutical characterization of formulations for the antiparasitic pyrethroid Deltamethrin.
Posterbeitrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Halle vom 10. – 13. Oktober 2001 in Halle/Saale. Abstract veröffentlicht in Arch. Pharm. 334 Suppl. 2, 80.
A. Koggel, C. Dressler, G. Peinhardt, H. Spahn-Langguth, P. Langguth (2001):
Affinities to the exsorptive transporter P-glycoprotein: 3H-Talinolol as radioligand in binding studies.
Posterbeitrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Halle vom 10. – 13. Oktober 2001 in Halle/Saale. Abstract veröffentlicht in Arch. Pharm. 334 Suppl. 2, 74.
A. Hanafy, P. Langguth, M. Abdel Aziz, H. Spahn-Langguth (2001):
Talinolol – a model ligand for P-glycoprotein in drug-drug interaction screening: PSC833, Cyclosporine A, Rifampicin, and verapamil versus vinblastine.
Posterbeitrag Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Halle vom 10. – 13. Oktober 2001 in Halle/Saale. Abstract veröffentlicht in Arch. Pharm. 334 Suppl. 2, 36.
T. Ohlig, G. Vergnault, P. Grenier, D. Scherer, P. Langguth (2001):
Nanosuspensions as promising peroral formulations for poorly soluble drugs: In-vitro solubility and intestinal transport studies.
Posterbeitrag 28th International Symposium on Controlled Release of Bioactive Materials in San Diego, 23.-27. Juni 2001.
D. Wagner, A. Hanafy, H. Spahn-Langguth, P. Langguth (2001):
Nonlinear model for intestinal absorption of actively and passively transported drugs using talinolol as model compound.
Poster Third European Graduate Student Meeting, Frankfurt/Main, 23. – 25. März, Abstract veröffentlicht in: Archiv der Pharmazie 333 (Suppl. 1), S. 15
2000
C. Tannergren, K.-J. Hoffmann, P. Langguth (2000):
Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity
Poster 46th Annual Congress of APV and APGI 9th International Conference on Pharmaceutical Technology, 3rd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Berlin, 3. – 6. April, veröffentlicht in Proceedings 3rd World Meeting APV/APGI, Berlin, pg. 775-776.
C. Dressler, A. Hanafy, S. Neuhoff, P. Langguth, H. Spahn-Langguth (2000):
Drug/Metabolite pairs: Comparison of their affinities to intestinal P-glycoprotein.
Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Münster, 4. – 7. Oktober, veröffentlicht in Archiv der Pharmazie 333 (Suppl. 2), S. 42.
C. Leisen, C. Dressler, B. Herber, P. Langguth, H. Spahn-Langguth (2000):
Correlation of lipophilicities of baclofen ester prodrugs and affinities to the ATP-dependent efflux pump P-glycoprotein.
Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Münster, 4. – 7. Oktober, veröffentlicht in Archiv der Pharmazie 333 (Suppl. 2), S. 50.
A. Koggel, S. Kober, H. Spahn-Langguth, P. Langguth (2000):
Carrier-mediated intestinal secretion of quarternary ammonium compounds as a limiting step in oral bioavailability?
Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Münster, 4. – 7. Oktober, veröffentlicht in Archiv der Pharmazie 333 (Suppl. 2), S. 64.
D. Wagner, A. Hanafy, H. Spahn-Langguth, P. Langguth (2000):
Talinolol permeability in different regions of the rat intestine.
Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Münster, 4. – 7. Oktober, veröffentlicht in Archiv der Pharmazie 333 (Suppl. 2), S. 67.
S. Kober, R. Butzer, C. Mang, T. Rönz, C. Hausdorf, P. Langguth, G.G. Belz, E. Mutschler (2000):
Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan.
Vortrag Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, 21.-23. März, veröffentlicht in Naunyn-Schmiedeberg´s Archives of Pharmacology Suppl to Vol 361, No. 4, 505.
1999
H. Spahn-Langguth, S. Döppenschmitt, B. Herber, P. Langguth (1999):
Higher brain tissue-to-blood ratios for baclofen esters as opposed to baclofen: Kinetics of baclofen methylester.
Poster 40. Frühjahrstagung der DGPT in Mainz, 9.-11. März 1999, veröffentlicht in Naunyn-Schmiedeberg´s Archives of Pharmacology, Suppl. to Volume 359, 3, R120
S.A. Döppenschmitt, A. Hanafy, P. Langguth, H. Spahn-Langguth (1999):
In vivo relevance of competitions at P-glycoprotein: Affinities of vinblastine and rhodamine 123, intestinal permeability and brain distribution.
Vortrag 40. Frühjahrstagung der DGPT in Mainz, 9.-11. März 1999, veröffentlicht in Naunyn-Schmiedeberg´s Archives of Pharmacology, Suppl. to Volume 359, 3, R120
P. Langguth (1999):
Biopharmazie - Perspektiven für das 21. Jahrhundert
APV/DPhG Hochschulforum „Pharmazeutische Technologie im 21. Jahrhundert“. 15. Januar 1999, Mainz.
P. Pietzonka, B. Rothen-Rutishauser, E. Walter, P. Langguth, H. Wunderli-Allenspach, H.P. Merkle (1999):
Particle uptake by the Caco-2-monolayer model: Fact or fiction?
Poster, CRS Kongress, Boston, veröffentlicht in Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials, #6340
S. Neuhoff, H. Spahn-Langguth, T.B. Andersson, C.G. Regårdh, P. Langguth (1999):
Grapefruit juice influences the intestinal permeability of the P-glycoprotein substrate talinolol: Mechanistic in-vitro studies and in-vivo relevance.
Poster, Second AAPS Frontier Symposium: Membrane Transporters and Drug Therapy, NIH, Bethesda, MD, 8. - 10. April.
S. Neuhoff, H. Spahn-Langguth, U. Norinder, C.G. Regårdh, T.B. Andersson, P. Langguth (1999):
Affinity of drugs to the intestinal multidrug carrier P-glycoprotein is predicted using MOLSURF parametrization.
Poster, Second AAPS Frontier Symposium: Membrane Transporters and Drug Therapy, NIH, Bethesda, MD, 8. - 10. April.
S. Neuhoff, H. Spahn-Langguth, U. Norinder, C.G. Regårdh, T.B. Andersson, P. Langguth (1999):
Computational approach to predicting affinity of drugs to P-glycoprotein suing Molsurf parametrization.
Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Frankfurt am Main, 6. - 9. Oktober, veröffentlicht in Archiv der Pharmazie Supplement 2/99, 121.
C. Dreßler, H. Spahn-Langguth, P. Ader, P. Langguth (1999):
Kinetics of the active losartan metabolite EXP3174 in rats following dosage of drug or metabolite.
Poster 40. Frühjahrstagung der DGPT in Mainz, 9.-11. März 1999, veröffentlicht in Naunyn-Schmiedeberg´s Archives of Pharmacology, Suppl. to Volume 359, 3, R120
1998
C. Dreßler, P. Langguth, H. Spahn-Langguth (1998):
The kinetics of losartan and its active metabolite EXP 3174 in rats: Intestinal versus hepatic processes.
Presentation First European Graduate Student Meeting, DPhG and EUFEPS, 20.-22. Feb., Frankfurt/Main
H. Eggers, H. Spahn-Langguth, V. Thiel, P. Langguth (1998):
Pharmacokinetics of tranylcypromine in rats: Site-dependent systemic availability after administration into the intestine.
Presentation First European Graduate Student Meeting, DPhG and EUFEPS, 20.-22. Feb., Frankfurt/Main
A. Hanafy, P. Langguth, H. Spahn-Langguth (1998):
The potential relevance of tissue P-glycoprotein in drug-drug interactions.
Presentation First European Graduate Student Meeting, DPhG and EUFEPS, 20.-22. Feb., Frankfurt/Main
C. Hilgendorf, H. Spahn-Langguth, P. Langguth (1998):
Transport studies on intestinal absorption: Caco-2/HT29-MTX cocultures as in-vitro alternative?
Presentation First European Graduate Student Meeting, DPhG and EUFEPS, 20.-22. Feb., Frankfurt/Main
S. Neuhoff, C. Regårdh, H. Spahn-Langguth, P. Langguth (1998):
The influence of grapefruit juice components on the intestinal permeability of the P-glycoprotein substrate talinolol.
Presentation First European Graduate Student Meeting, DPhG and EUFEPS, 20.-22. Feb., Frankfurt/Main
A. Hanafy, P. Langguth, H. Spahn-Langguth (1998):
Tissue distribution of the P-glycoprotein substrate talinolol in rats: Influence of verapamil.
Poster, 39. Frühjahrstagung der DGPT, Mainz, 17. - 19. März 1998; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 357 (4) Suppl., R7
C. Dreßler, P. Langguth, P. Ader, H. Spahn-Langguth (1998):
Losartan and its active metabolite EXP3174: Estimation of partial clearances in in-vitro and in-vivo rat studies
Poster, 39. Frühjahrstagung der DGPT, Mainz, 17. - 19. März 1998; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 357 (4) Suppl., R6
C. Hilgendorf, H. Spahn-Langguth, P. Langguth (1998):
Caco-2 and HT29-MTX cells and their cocultures as permeability screens for carrier-mediated and passive intestinal transport
Poster, 39. Frühjahrstagung der DGPT, Mainz; 17. - 19. März 1998; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 357 (4) Suppl., R7
P. Langguth, S. Neuhoff, C. Regårdh, H. Spahn-Langguth, (1998):
Grapefruit juice components modify the intestinal permeability of the P-glycoprotein substrate talinolol.
Poster 15. Treffen der European Intestinal Transport Group (EITG), Sundvollen, Norwegen, 17. - 21. Mai 1998; Veröffentlicht in: Zeitschrift für Gastroenterologie 36 (4) 337
J. Heizmann, H.P. Merkle, P. Langguth (1998):
Permeation of thymopoietin oligopeptides across Caco-2 cell monolayers
Poster, 25. International Symposium on Controlled Release of Bioactive Materials, CRS, Las Vegas; Veröffentlicht in: Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 25: 681-682 (1998)
Anderle, W. Rubas, H.P. Merkle, F. Largiadèr, P. Langguth (1998):
Stability and absorption of IGF-1 in the gastrointestinal tract
Poster Proc. 2nd World Meeting APV/APGI, Paris.
A. Hanafy, P. Langguth, H. Spahn-Langguth (1998):
Interactions between P-glycoprotein substrates: R-talinolol- and cyclosporine A related changes of S-talinolol tissue distribution and intestinal permeability in rats.
Doktorandentagung der DPhG in Freiburg
S. Döppenschmitt, H. Eggers, B. Herber, P. Langguth, H. Spahn-Langguth (1998):
Enantioselektive GC-ECD Bestimmung für Ester des Baclofens in biologischem Material: Trennung der Pentafluorpropionsäure-Amide an CHIRASIL-VAL.
APV Workshop „Bioanalytische Methoden“, Eisenach/Wartburg 28.-29. September 1998.
1997
C. Hilgendorf, S. Döppenschmitt, H. Spahn-Langguth, E. Lipka, M.A. Croyle, G.L. Amidon, P. Langguth (1997):
Intestinal transport studies with talinolol enantiomers: Comparison of Caco-2 and Caco-2/HT29-MTX co-cultured cell lines
Poster, ISSX Meeting, Göteborg, 30. Juni - 3. Juli; Veröffentlicht in ISSX Proceedings, Volume 11, 123
P. Anderle, E. Niederer, H. Spahn-Langguth, H. Wunderli-Allenspach, H.-P. Merkle, P. Langguth (1997)
The influence of culturing conditions and drug exposure on P-gp expression in Caco-2 cells.
Poster, 24. International Symposium on Controlled Release of Bioactive Materials, CRS, Stockholm, 15.-19. Juni; Veröffentlicht in Proceed. 24th Intern. Symp. Bioact. Mater., 323-324
P. Ader, G. Baktir, A. Radschuweit, B. Terhaag, P. Langguth, H. Spahn-Langguth (1997):
Hemmung P-glycoprotein-abhängiger Transportprozesse durch Verapamil: Beeinflussung der Kinetik von Talinolol bei der Ratte
Vortrag, Doktorandentagung der DPhG, Würzburg, 14.-16. März
R. Weyhenmeyer, G. Krumbiegel, W. Lang, W. Wächter, P. Langguth (1997):
Studies on the intestinal absorption of the quaternary trospium chloride from aqueous solution and novel formulations
Poster, 38. Frühjahrstagung der DGPT, Mainz, 10.-13. März; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 355 (4) Suppl., R10
B. Herber, H. Spahn-Langguth, J. Röhrich, G. Kauert, P. Langguth (1997):
Distribution of i.p. and nasal cocaine into the CNS of rats: Increased tissue-to-blood ratios after application on the nasal mucosa
Poster, 38. Frühjahrstagung der DGPT, Mainz, 10.-13. März; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 355 (4) Suppl., R8
S. Döppenschmitt, R. Port, P. Langguth, C.A. Baldamus, E. Mutschler, H. Spahn-Langguth (1997)
Pharmacokinetics of hydroxyzine and its active metabolite cetrizine in healthy volunteers and patients with renal insufficiency
Kurzvortrag, 38. Frühjahrstagung der DGPT, Mainz, 10.-13. März; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 355 (4) Suppl., R453
C, Hilgendorf, H. Spahn-Langguth, P. Langguth (1997)
Intestinal secretion of talinolol: Competitive and P-gp-antibody-induced inhibition of transport in studies with Caco-2 cells
Kurzvortrag, 38. Frühjahrstagung der DGPT, Mainz, 10.-13. März; Veröffentlicht in: Naunyn-Schmiedeberg’s Archives of Pharmacology 355 (4) Suppl., R480
P. Ader, G. Baktir, A. Raduschweit, B. Terhaag, P. Langguth, H. Spahn-Langguth (1997)
Hemmung P-glycoproteinabhängiger Transportprozesse durch Verapamil: Beeinflussung der Kinetik von Talinolol bei der Ratte
Kurzvortrag, 9. Frühjahrstagung der DPhG, Julius-Maximilians-Universität Würzburg, 13.-16. März
S. Döppenschmitt, R. Port, P. Langguth, C.A. Baldamus, E. Mutschler, H. Spahn-Langguth (1997)
Hydroxyzin und sein aktiver Metabolit Cetrizin: Reduzierte renale Clearance von Cetrizin bei verminderter Creatinin-Clearance?
Kurzvortrag, 9. Frühjahrstagung der DPhG, Julius-Maximilians-Universität Würzburg, 13.-16. März
C. Hilgendorf, H. Spahn-Langguth, P. Langguth (1997)
Beeinflussung P-glycoprotein-abhängiger Transportprozesse in Caco-2-Zell-Monolayern: Untersuchungen mit Talinolol-Enantiomeren
Kurzvortrag, 9. Frühjahrstagung der DPhG, Julius-Maximilians-Universität Würzburg, 13.-16. März
S. Döppenschmitt, R. Port, P. Langguth, C.A. Baldamus, E. Mutschler, H. Spahn-Langguth (1997)
Hydroxyzin und sein aktiver Metabolit Cetrizin: Reduzierte renale Clearance von Cetrizin bei verminderter Creatinin Clearance?
Kurzvortrag, 9. Frühjahrstagung der DPhG, Julius-Maximilians-Universität Würzburg, 13.-16. März
B. Herber, H. Spahn-Langguth, F. Röhrich, G. Kauert, P. Langguth (1997):
Verteilungsverhalten von Kokain in das ZNS nach i.p. und nasaler Gabe bei Ratten: Höhere Gewebe-Blut Quotienten nach Applikation auf die Nasalmukosa
Poster, X. Symposium der Gesellschaft für Toxikologische und Forensische Chemie, GTFCH, Mosbach, 18.-19. April, veröffentlicht in: GTFCH-Symposium Moderne Meßverfahren im Rahmen der Toxikologisch-Forensischen Begutachtung, Hrsg. Fritz Pragst, Helm Verlag
B. Herber, A. Hanses, J. Röhrich, H. Spahn-Langguth, G. Kauert, P. Langguth (1997):
Anwendung einer Festphasenextraktionsmethode für pharmakologische und toxikologische Problemstellungen in komplexen biologischen Matrizes
Poster, X. Symposium der Gesellschaft für Toxikologische und Forensische Chemie, Mosbach, 18.-19. April, veröffentlicht in: GTFCH-Symposium Moderne Meßverfahren im Rahmen der Toxikologisch-Forensischen Begutachtung, Hrsg. Fritz Pragst, Helm Verlag
P. Langguth, P. Ader, G. Baktir, A. Okyar, A. Radschuweit, H. Spahn-Langguth (1997):
Inhibition of P-glycoprotein-dependent transport processes by verapamil: Influence on the pharmacokinetics of talinolol in the rat
Poster, Symposium The Impact of Pharmacokinetics in Modern Drug Development, San Francisco, 16.-17. Mai
1996
J. Heizmann, S. Wolffram, H.P. Merkle, P. Langguth (1996):
Enzymatic stability of thymopoietin epitopes in the gastrointestinal tract.
Vortrag, 42. Annual Congress of APV, Mainz, 8. März 1996
S. Lang, P. Langguth, R. Oschmann, B. Traving, H.P. Merkle (1996):
Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa.
Vortrag, 42. Annual Congress of APV, Mainz, 8. März 1996
P. Anderle, E. Niederer, H.P. Merkle, P. Langguth (1996):
Expression of bioavailability-limiting ATP-dependent efflux pump in intestinal epithelium.
Poster, 42. Annual Congress of APV, Mainz, 8. März 1996
B. Herber, H. Spahn-Langguth, P. Langguth (1996):
Höhere Gewebe/Blut-Quotienten im ZNS nach Applikation auf die Nasalmukosa: Vergleich von Baclofen mit Tranylcypromin.
Poster, 37. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Mainz, 12.-14. März 1996
P. Anderle, E. Niederer, H. Spahn-Langguth, H.P. Merkle, P. Langguth (1996):
P-Glycoprotein als Bioverfügbarkeits-limitierender Carrier: Expression in Epithelzellen des Intestinums.
Poster, 37. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Mainz, 12.-14. März 1996
H. Spahn-Langguth, P. Langguth, J. Schloos (1996):
Signifikanter Beitrag zur Blockade durch Carvedilol-Metabolite: Hinweise aus p.o.- und i.v.-Daten.
Poster, 37. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Mainz, 12.-14. März 1996
Y. Taki, S. Yamashita, T. Sakane T. Nadai, H. Sezaki, P. Langguth, Gordon L. Amdion (1996):
Degradation and absorption of peptide drugs in Caco-2 monolayer - evaluation of oral activity.
Poster, 23rd. International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 7. - 10. July 1996; Veröffentlicht in Proceed. Intern. Symp. Bioact. Mater. (1996) 585-586
H. Heizmann, S. Wolffram, H.P. Merkle, P. Langguth (1996):
Enzymatic degradation of thymopoietin oligopeptides in the gastrointestinal tract.
Poster, 23rd. International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 7. - 10. July 1996; Veröffentlicht in Proceed. Intern. Symp. Bioact. Mater. (1996) 591-592
J. Schloos, H. Spahn-Langguth, P. Langguth (1996):
Contribution of drug metabolites to b-adrenoceptor antagonism: Carvedilol p.o. vs. i.v. data and influence of cimetidine on the b1-RRA/HPLC correlation of p.o. carvedilol.
Vortrag, Läkemedelkongressen, Apotekarsocieteten, Stockholm, 11.-13. November
B. Herber, H. Spahn-Langguth, P. Langguth (1996):
Higher CNS-selectivity following application on the nasal mucosa: Cocaine
Poster, Läkemedelkongressen, Apotekarsocieteten, Stockholm, 11.-13. November
B. Herber, H. Spahn-Langguth, P. Langguth (1996):
CNS-Targeting following application on the nasal mucosa: Tranylcypromine
Poster, Läkemedelkongressen, Apotekarsocieteten, Stockholm, 11.-13. November
1995
P. Langguth, H. Spahn-Langguth (1995):
Brain targeting of drugs: Better access to the CNS via the nasal mucosa?
Poster, 36. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 14. - 17. März 1995
U. Wetterich, E. Mutschler, H. Spahn-Langguth, P. Langguth (1995):
Evidence for intestinal secretion of the ß-adrenoceptor antagonist talinolol: Data from humans and studies with Caco-2 cells.
Vortrag, 36. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 14. - 17. März 1995
U. Wetterich, E. Mutschler, H. Spahn-Langguth, P. Langguth (1995):
Untersuchungen zur intestinalen Sekretion des ß-Adrenozeptorantagonisten Talinolol: Humandaten und Studien mit Caco-2-Zellen.
Poster, Doktorandentreffen der Deutschen Pharmazeutischen Gesellschaft, Kloster Banz, Staffelstein, 9. - 11. März 1995
H. Spahn-Langguth, U. Wetterich, E. Mutschler, P. Langguth (1995):
Intestinal secretion of the ß-adrenoceptor antagonist talinolol: Concentration-dependent transport through Caco-2 monolayers and dose-dependent bioavailability in vivo.
Poster, 13. European Intestinal Transport Group Meeting, Otranto, 21. - 25. Mai 1995
V. Bohner, H.P. Merkle, P. Langguth (1995):
Absorption of intact enkephalin pentapeptides through Caco-2 monolayers and transport modulation by P-glycoprotein.
Poster, 13. European Intestinal Transport Group Meeting, Otranto, 21. - 25. Mai 1995
V. Bohner, B. Roten-Rutishauser, J.C. Perriard, H. Wunderli-Allenspach, H.P. Merkle, P. Langguth (1995):
Paracellular transport and other mechanisms involved in intestinal peptide absorption.
Poster, 1st World Meeting on Pharmaceutics, Biopharmaceutics, Pharmaceutical Technology, Budapest, 9.-11. Mai 1995
V. Bohner, B. Roten-Rutishauser, J.C. Perriard, H. Wunderli-Allenspach, H.P. Merkle, P. Langguth (1995):
Intestinal transport mechanism of peptides across Caco-2 cell monolayers and visualization by confocal laser scanning microscopy.
Poster, 22nd Int. Symp. Contr. Rel. Bioact. Mater., Seattle, 30. Juli - 2. Aug. 1995
H.L. Lueßen, V. Bohner, D. Perard, P. Langguth, J. Verhoef, A.G. de Boer, H.P. Merkle, H.E: Junginger (1995):
Effect of polyacrylates on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles.
Poster, 22nd Int. Symp. Contr. Rel. Bioact. Mater., Seattle, 30. Juli - 2. Aug. 1995
H.L. Lueßen, V. Bohner, D. Pérard, P. Langguth, J. Verhoef, A.G. de Boer, H.P. Merkle, H.E. Junginger (1995):
Protection of peptide drugs from intestinal brush-border membrane vesicle degradation by poly(acrylates).
Poster, Special Symposium on Current Topics in Peptide Delivery CRS Ireland, 20. Sept. - 22. Sept. 1995
V. Bohner, B. Roten-Rutishauser, J.C. Perriard, H. Wunderli-Allenspach, H.P. Merkle, P. Langguth (1995):
Intestinal oligopeptide absorption: Transport mechanism and pathways.
Poster, 3rd Meeting on Peptide and Protein Drugs, Industry-Academia, Zürich, 29. Mai 1995 /1994
P. Langguth, H.P. Merkle, S. Wolffram:
Peptide mucosal absorption and metabolism: Differences in small and large intestinal permeability and degradation of oligopeptides and implications for oral drug delivery.
Poster 40. Jahreskongress der APV in Mainz, 9.-12. März 1994
P. Langguth, G. Hahn, W. Möhrke, H.P. Merkle, H. Möhler, H. Spahn-Langguth:
Absorption-site and absolute bioavailability: Pharmacokinetics of tranylcypromine after intestinal and nasal applications.
Vortrag, 40. Jahreskongress der APV in Mainz, 9.-12. März 1994
H. Spahn-Langguth, K.M. Lee, G.L. Amidon, P. Langguth:
Discontinuous oral absorption profiles: Dependence on gastrointestinal motility.
Poster, 40. Jahreskongress der APV in Mainz, 9.-12- März 1994
V. Bohner, P. Langguth, J. Biber, H.P. Merkle:
Intestinal absorption and metabolism of pentapeptides.
Poster, 40. Jahreskongress der APV in Mainz, 9.-12. März 1994
P. Langguth, H. Spahn-Langguth, K.M. Lee, G.L. Amidon:
Gastrointestinal motility and discontinous absorption-profiles: Simulation with varying elimination half-lives.
Poster, Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie, Mainz, 14.-18. März 1994
H. Spahn-Langguth, G. Hahn, H. Möhler, P. Langguth:
Tranylcypromine pharmacokinetics in rats: Stereoselectivity of clearance and first-pass effect.
Poster, Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie, Mainz, 14.-18. März 1994
P. Langguth, H.P. Merkle, A. Stöckli, S. Wolffram:
Absorption from ascending colon and first-pass extraction of a pentapeptide drug.
Poster, 21. Int. Symp. Contr. Rel. Bioact. Mater., Nizza, 27.-30. Juni 1994
Y. Taki, S. Yamashita, T. Sakane, T. Nadai, H. Sezaki, P. Langguth, G.L. Amidon:
Gastrointestinal absorption of metkephamid - Quantitative evaluation of degradation and permeation.
Poster, 21. Int. Symp. Contr. Rel. Bioact. Mater., Nizza, 27.-30. Juni 1994
V. Bohner, P. Langguth, J. Biber, H.P. Merkle:
Intestinal mucosal transport and metabolism of pentapeptides.
Poster, 21. Int. Symp. Contr. Rel. Bioact. Mater., Nizza, 27.-30. Juni 1994
H. Spahn-Langguth, G. Hahn, W. Möhrke, P. Langguth:
Variabilities and discontinuities in tranylcypromine input profiles following oral dosage.
Poster, 2. European Congress of Pharmaceutical Sciences, Berlin, 29. September - 1. Oktober 1994
E. Lipka, P. Langguth, H. Spahn-Langguth, E. Mutschler, G.L. Amidon:
Celiprolol double peak occurrence and gastric motility: Nonlinear mixed effect modeling of bioavailability data obtained in dogs.
Poster, 2. European Congress of Pharmaceutical Sciences, Berlin, 29. September - 1. Oktober 1994
1993
P. Langguth, H. Spahn-Langguth, K.M. Lee, T.S.-H. Chen, N. Najib, G.L. Amidon:
Cimetidine absorption in the dog: Evaluation of a two-lag-time model for plasma profiles after gastric and duodenal administration.
Poster, 34. Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie in Mainz, 16.-18. März, 1993
P. Langguth, G.L. Amidon, R. Büschges, G. Hahn, E. Mutschler, H. Spahn-Langguth: Fluorescent derivatization of primary amines with o-phthaldialdehyde: Bioanalytical and pharmacokinetic studies with metkephamid and tranylcypromine.
Poster, 4. International Symposium on Pharmaceutical and Biomedical Analysis, Baltimore, Maryland, 18. - 21. April 1993
P. Langguth, V. Bohner, J. Biber, H.P. Merkle:
The use of intestinal brush border membrane vesicles to study the metabolism and transport of peptides.
Poster, 2. Treffen Pharma-Proteine und -Peptide, Hochschule-Industrie, Zürich, 15. April 1993
P. Langguth, V. Bohner, J. Biber, G.L. Amidon, H.P. Merkle:
Experimental approach to evaluate intestinal metabolism and transport: peptide compounds.
Vortrag, 2. Treffen Pharma-Proteine und -Peptide, Hochschule-Industrie, Zürich, 15. April 1993
P. Langguth, H.P. Merkle, G.L. Amidon:
Site-dependent intestinal metabolism and absorption of the pentapeptide metkephamid.
Vortrag, 20th. International Symposium on Controlled Release of Bioactive Materials, Washington, 25.-28. Juli 1993
E. Lipka, I. Lee, H. Spahn-Langguth, P. Langguth, E. Mutschler, G.L. Amidon:
The influence of gastric motility on the pharmacokinetics of celiprolol.
Poster, 8. Treffen der American Association of Pharmaceutical Scientists (AAPS) in Orlando, Florida, 14. -18. November 1993
H. Spahn-Langguth, G.L. Amidon, P. Langguth:
Die Pharmakokinetik von Cimetidin in Abhängigkeit von der gastrointestinalen Motilität: Anwendung der Momentanalyse bei diskontinuierlichen Absorptionsprofilen.
Poster, Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Saarbrücken, 22. - 25. September 1993
Y. Taki, S. Yamashita, T. Sakane, T. Nadai, H. Sezaki, P. Langguth:
Gastrointestinal absorption of peptide drugs. Quantitative evaluation for metabolism and membrane permeation.
Poster, 8. Jahreskongress der Japanese Society for the Study of Xenobiotics, Chiba, Japan, 27. - 29. Oktober 1993
1992
G. Hahn, P. Langguth, W. Möhrke:
Enantiospezifische fluorimetrische Bestimmungsmethode für Norephedrin (Phenylpropanolamin) und ihre Anwendung in pharmakokinetischen Studien.
Poster, 33. Jahrestagung der Deutschen Pharmakologischen Gesellschaft in Mainz, 10.-12. März 1992
C. Gido, P. Langguth, H.P. Fortmeyer, E. Mutschler:
Flow through dissolution system for prediction of pharmacokinetics of doxepin following application of slow release i.m. formulations.
Poster, 38. Jahreskongress der APV in Regensburg, 1.-4. April 1992
H. Spahn-Langguth, G. Hahn, P. Langguth, W. Möhrke:
Stereospecific o-phthaldialdehyde assay for drugs -including peptides- with primary amine groups and its applicability to biopharmaceutics.
Poster, 38. Jahreskongress der APV in Regensburg, 1.-4. April 1992
P. Langguth, V. Bohner, J. Biber, H.P. Merkle:
The use of intestinal brush border membrane vesicles to study the metabolism and transport of peptides.
Poster, 38. Jahreskongress der APV in Regensburg, 1.-4. April 1992
P. Langguth, R. Alder, H.P. Merkle:
Kinetics and mechanisms of aspartame degradation in aqueous solutions.
Poster, 38. Jahreskongress der APV in Regensburg, 1.-4. April 1992
H. Spahn-Langguth, G. Hahn, P. Langguth, W. Möhrke, E. Mutschler:
Stereospecific o-phthaldialdehyde assay for drugs -including peptides- with primary amine groups and its applicability to biopharmaceutics.
Poster, 1. European Congress of Pharmaceutical Science, Amsterdam, 7.-9. Oktober, 1992
1991
P. Langguth, J. Biber, H.P. Merkle:
Chemische und enzymatische Stabilität von Peptiden in Lösung und bei der Permeation biologischer Grenzflächen.
Vortrag, Erstes Treffen "Pharma-Proteine und -Peptide, Hochschulen - Industrie", ETH Zürich, März 1991
P. Langguth, V. Bohner, J. Biber, H.P. Merkle:
Metkephamid hydrolytic stability, degradation by luminal and brush border enzymes, and uptake by the intestinal brush border: Implications for oral systemic availability of opioid peptides.
Poster, Pharmacy World Congress 91 der FIP, Washington DC, 1.-6. September 1991
H. Spahn-Langguth, G. Hahn, E. Mutschler, W. Möhrke, P. Langguth:
Enantiospecific fluorescence assay for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies.
Poster, Pharmacy World Congress 91 der FIP, Washington DC, 1.-6. September 1991
1990
P. Langguth, P.J. Khan, E.R. Garrett:
Pharmakokinetik von Morphin und seinen Abkömmlingen am Hund: Beeinflussung der Pharmakokinetik und -dynamik von Morphin durch Naltrexon.
Poster, 35. Jahrestagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie in Mainz, März 1990
1989
H. Spahn, E. Martin, D. Krauß, E. Mutschler, P. Langguth:
Derivate von 2-Arylpropionsäuren als chirale Reagenzien: Reaktivität und chromatographisches Verhalten der Umsetzungsprodukte.
Vortrag, Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Frankfurt, September 1989
P. Langguth, H. Spahn, E. Mutschler, H.P. Merkle:
Amino acid analysis in protein and peptide stability studies: Enantiospecific HPLC assay using flunoxaprofen as fluorescent label.
Vortrag, 49. Int. Kongress der FIP, München, September 1989
1985
P. Langguth:
Untersuchungen zur Variation der transepidermalen Permeation von Arzneistoffen.
Vortrag, Jahrestagung der Deutschen Pharmazeutischen Gesellschaft in Braunschweig, September 1985